Clinical Trial Update: Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating methylprednisolone with or without doxorubicin for metastatic prostate cancer. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• METHYLPREDNISOLONE (methylprednisolone)

Snippet

Sponsor: UNICANCER | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED